Buprenorphine · larger labeled portfolio than Buprenorphine/Naloxone
SPL labels Buprenorphine/Naloxone + Buprenorphine as minor; Buprenorphine/Naloxone 19 / Buprenorphine 28 in that band.
Mechanism on file: Taking these medicines together can slow down how your body breaks down the drug, leading to higher levels in your blood. This can make the opioid effects stronger or last longer than they should.
FDA SPL severity: Minor
Buprenorphine/Naloxone + Buprenorphine · SPL mechanism field
Taking these medicines together can slow down how your body breaks down the drug, leading to higher levels in your blood. This can make the opioid effects stronger or last longer than they should.
Minor band excerpt · Buprenorphine/Naloxone with Buprenorphine
If concomitant use is warranted, strongly consider recommending or prescribing an opioid overdose reversal agent, as is recommended for all patients on buprenorphine treatment for opioid use disorder [see Warnings and Precautions ( 5.2 )] . Inhibitors of CYP3A4 Clinical Impact: The concomitant use of buprenorphine and CYP3A4 inhibitors can increase the plasma concentration of buprenorphine, resulting in increased or prolonged opioid effects, particularly when an inhibitor is added after a stable dose of SUBOXONE sublingual film is achieved. After stopping a CYP3A4 inhibitor, as the effects...
Buprenorphine/Naloxone · 19 minor + 19 total pairs
- Carbamazepine minor
- Cyclobenzaprine minor
- Darunavir minor
- Erythromycin minor
Buprenorphine · 29 SPL pairs (broader portfolio than Buprenorphine/Naloxone)
- Alprazolam minor
- Buprenorphine (Pain) minor
- Carbamazepine minor
- Codeine minor
FDA Drug Labels (SPL) via openFDA. Registry display only. Not medical advice.
Read our methodology - how this data is sourced, computed, and verified.